Cord Blood

Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.

TreeFrog Therapeutics brings in senior profiles to drive the advent of high-quality & affordable allogenic cell therapies

February 5, 2020 By Cade Hildreth, Founder & President Leave a Comment

Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-Stem^TMtechnology for cell therapy mass-production.

Bordeaux, France, February 5, 2020 – TreeFrog Therapeutics, a pure player in iPSC-derived cell therapies, today announces the appointment of 2 senior executives and 2 independent board members. Pascale Berthet, formerly Business Development Manager at FUJIFILM Cellular Dynamics was appointed Chief Business Development Officer, and Michaël Lanero Fidalgo, former Head of EMEA Biodevelopment Center at Merck KGaA, was recruited as Chief Operating Officer. In addition, 2 independent board members joined TreeFrog Therapeutics’ corporate governance: Julia Berretta, formerly VP of Business Development at Cellectis, and Frederic Desdouits, former Bionest Partner and Pierre Fabre North America director. [Read more…]

International Perinatal Stem Cell Society to Host Two Scientific Conferences in 2020

December 21, 2019 By Cade Hildreth, Founder & President Leave a Comment

Kyle Cetrulo, President, International Perinatal Stem Cell Society

The International Perinatal Stem Cell Society is a non-profit organization founded on the principle that stem cells from perinatal tissues contain enormous, untapped potential to treat many diseases and disorders worldwide.

For many years, the Perinatal Stem Cell Society has been hosting an annual conference featuring the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific programs cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices.

Below, Kyle Cetrulo, President of the International Perinatal Stem Cell Society, explains the future of perinatal stem cell science and the role that the Society’s 2020 Scientific Conferences will play in advancing this mission. [Read more…]

CBR Announces New Pediatric Genetic Screening Test in Collaboration with Sema4

November 20, 2019 By Cade Hildreth, Founder & President Leave a Comment

Sema4 collaborated with CBR to launch ReadyGen™, a genetic screening test that analyzes a child’s DNA for 200+ conditions.

LOS ANGELES, Nov. 15, 2019 — CBR, the global leader in newborn stem cell banking, has announced a new genetic service developed over the past couple of years as part of a strategic alliance with Sema4. As a patient-centered health intelligence company and leading innovator within the genomic testing industry, Sema4 collaborated with CBR to launch ReadyGen™, a highly accurate genetic screening test that analyzes a child’s DNA for more than 200 conditions that can affect children before the age of 10. [Read more…]

Cesca Partners with Healthbank Biotech (Stem Cell Bank) to Provide Immune Cell Banking

November 18, 2019 By Cade Hildreth, Founder & President Leave a Comment

ImmuneCyte to Begin Operations in Fourth Quarter of 2019

RANCHO CORDOVA, Calif., Oct. 22, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture agreement with HealthBanks Biotech (USA) Inc., one of the world’s leading stem cell bank networks, to commercialize its proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). The joint venture will be named ImmuneCyte Life Sciences Inc. (“ImmuneCyte”) and is expected to officially launch during the fourth quarter of 2019. [Read more…]

CBR to Acquire Natera’s Evercord™ Cord Blood Business for an Undisclosed Sum

November 12, 2019 By Cade Hildreth, Founder & President Leave a Comment

Cord Blood Registry (CBR), a California Cryobank Life Sciences company, has announced it will acquire Natera’s Evercord™ cord blood business for an undisclosed sum. CBR is the largest newborn stem cell collection and storage company within the United States with more than 875,000 stem cell samples in storage. Natera is a publicly listed company (NASDAQ: NTRA) that specializes in genetic testing services. [Read more…]

Cord Blood

Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-StemTM technology for cell therapy mass-production.

Sema4 collaborated with CBR to launch ReadyGen™, a genetic screening test that analyzes a child’s DNA for 200+ conditions.

ImmuneCyte to Begin Operations in Fourth Quarter of 2019

Senior profiles from Merck KGaA and FUJIFILM Cellular Dynamics join in to accelerate the global dissemination of proprietary C-Stem^TMtechnology for cell therapy mass-production.